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Abstract
Introduction: Candida lusitaniae was originally described as a human pathogen in 1979 and typically
affects immunocompromised patients.
Case presentation: We describe a case of prosthetic valve endocarditis with Candida lusitaniae in
an immunocompetent 62-year-old woman following aortic valve replacement. In vitro testing
demonstrated that our isolate was sensitive to amphotericin B, caspofungin and fluconazole.
Conclusion: The infection was lethal despite aggressive medical and surgical management and
sterilization of blood cultures. The outcome of our case illustrates the need to recognize Candida
lusitaniae fungemia as a life-threatening infection in a patient with a prosthetic aortic valve.
Introduction
Candida species are the most frequent causes of fungal
endocarditis. Mortality from Candida endocarditis has been
reportedatarateof50-80%[1].Candidaalbicansisthemost
frequently isolated species, followed by C. parapsilosis,
C. glabrataand C.tropicalis. C.lusitaniae, originallydescribed
as a human pathogen in 1979, typically affects immuno-
compromised patients and accounts for less than 5% of
all invasive Candida infections [2,3]. Infections including
meningitis, osteomyelitis and peritonitis have been
reported, but the most common presentation of this
pathogenisfungemiainpatientsundergoingchemotherapy
for cancer [4-6]. Prosthetic valve endocarditis with this
organism has been described only once previously [7].
Although resistance to amphotericin B has been reported,
a recent susceptibility study has shown that the majority of
C. lusitaniae isolates are flucytosine resistant and amphoter-
icin-B susceptible [8]. In contrast, in vitro testing of the
isolateinthiscase demonstratedsensitivity to amphotericin
B, caspofungin and fluconazole.
Case presentation
A 62-year-old Caucasian woman presented with a two-
month history of intermittent fever. Her past medical
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artery disease and mild chronic kidney disease. She was
found to have Enterococcus faecalis endocarditis of her
native, bicuspid, aortic valve. She was treated with
vancomycin, gentamicin and penicillin and subsequently
underwent aortic valve replacement (AVR) with a Saint
Jude valve in October of 2004. Her postoperative course
was complicated by evacuation of a mediastinal hema-
toma, splenectomy and a partial colectomy with diverting
colostomy for hemorrhagic colitis. The patient had been
discharged and re-admitted multiple times and was
ultimately transferred to the Oklahoma University Medical
Center in May 2005.
Upon transfer, the patient complained of dyspnea,
orthopnea and lower-extremity swelling. She was afebrile
and hemodynamically stable. Her physical examination
revealed jugular venous distention, a III/VI systolic
murmur in the right second intercostal space, and bilateral
lower-extremity edema to the knees. No peripheral
stigmata of endocarditis were identified.
Nine blood cultures obtained over a five-day period were
positive for Candida lusitaniae. Susceptibility testing was
performed on the initial isolate only and revealed
sensitivity to amphotericin B, caspofungin and flucona-
zole (Table 1). Transesophageal echocardiography
revealed multiple vegetations on a partially dehiscent
mechanical aortic valve (Figure 1) with severe aortic
valvular regurgitation and a left ventricular ejection
fraction of 50% (Figure 2). Therapy with caspofungin
was initiated prior to obtaining results of susceptibility
testing on the initial isolate and was continued based on
the minimal inhibitory concentration (MIC). The patient
eventually underwent repeat AVR with coronary artery
bypass grafting. Vegetations were noted on her removed
prosthetic valve (Figures 3 and 4). Her post-operative
course was complicated by a chest hematoma which was
evacuated. Despite eventual clearance of her fungemia, the
patient died from multi-organ failure in June 2005.
Discussion
It remains unknown whether the source of our patient’s
fungemia was her abdominal surgery or a central venous
catheter infection. Transesophageal echocardiography was
helpful in identifying prosthetic valve infection and
dysfunction. MIC testing of the initial fungal isolate
demonstrated susceptibility to multiple antifungals.
Potential biofilm formation on the prosthetic valve
could have resulted in a discrepancy between the MIC
derived from the blood isolate and the isolate at the site of
infection, although the latter was not submitted for
testing. Aggressive surgical management and antifungal
treatment led to clearance of our patient’s fungemia.
Nevertheless, the infection resulted in a lethal outcome as
in the previously described case [7]. The shared outcome
of our case with that of the previous case clearly illustrates
Table 1. MICs and minimum fungicidal concentrations for Candida lusitaniae
isolate from May 2005
Agent Parameter, value (mcg/mL)
Amphotericin B MIC 0.50
MFC 0.50
Caspofungin MIC 0.06
MFC ND
Fluconazole MIC 0.25
MFC ND
Note: Susceptibility of blood culture isolate to Caspofungin performed by
the Fungus Testing Lab, UTHSC, San Antonio, TX. All other suscept-
ibilities of blood culture isolate were determined by Microbiology
Laboratory at OU Medical Center, Oklahoma City, OK.
MFC = minimum fungicidal concentration. ND = Not done.
Figure 1. Trans-esophageal echocardiographic image of
prosthetic aortic valve vegetations. White arrow indicates
largest fungal vegetation identified in this case.
Figure 2. Infected prosthetic aortic valve regurgitation.
Trans-esophageal echocardiography was helpful in
identification of the prosthetic valve infection and dysfunction.
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threatening infection in a patient with a prosthetic aortic
valve.
Conclusion
We describe a case of prosthetic valve endocarditis with
Candida lusitaniae following AVR in an immunocompetent
patient. To our knowledge, this is only the second reported
case of prosthetic valve endocarditis due to this uncom-
mon Candida species. In vitro testing demonstrated that
our isolate was sensitive to amphotericin B, caspofungin
and fluconazole. As in the previously described case, this
infection was lethal despite aggressive medical and
surgical management and sterilization of blood cultures.
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Figure 3. Infected prosthetic aortic valve. Notice the
irregularities on the leaflet surfaces of the removed prosthetic
valve.
Figure 4. Prosthetic aortic valve vegetation. Black arrow
indicates a vegetation on the removed prosthetic valve.
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